Trial · NCT04885998
Participant flow20
How many started, completed or left each group, period by period.
1 to 20 of 20
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 | 7 | |
| Overall Study | STARTED | Part 1 Cohort 2: Tarlatamab Dose A/Dose C + AMG 404 | 5 | |
| Overall Study | STARTED | Part 1 Cohort 3: Tarlatamab Dose A/Dose D + AMG 404 | 3 | |
| Overall Study | STARTED | Part 2 Dose Expansion Cohort: Tarlatamab Dose A/Dose B + AMG 404 | 8 | |
| Overall Study | Safety Analysis Set | Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 | 7 | |
| Overall Study | Safety Analysis Set | Part 1 Cohort 2: Tarlatamab Dose A/Dose C + AMG 404 | 5 | |
| Overall Study | Safety Analysis Set | Part 1 Cohort 3: Tarlatamab Dose A/Dose D + AMG 404 | 3 | |
| Overall Study | Safety Analysis Set | Part 2 Dose Expansion Cohort: Tarlatamab Dose A/Dose B + AMG 404 | 8 | |
| Overall Study | Entered Extended Safety Period (EP) | Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 | 6 | |
| Overall Study | Entered Extended Safety Period (EP) | Part 1 Cohort 2: Tarlatamab Dose A/Dose C + AMG 404 | 1 | |
| Overall Study | Entered Extended Safety Period (EP) | Part 1 Cohort 3: Tarlatamab Dose A/Dose D + AMG 404 | 1 | |
| Overall Study | Entered Extended Safety Period (EP) | Part 2 Dose Expansion Cohort: Tarlatamab Dose A/Dose B + AMG 404 | 4 | |
| Overall Study | COMPLETED | Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 | 3 | |
| Overall Study | COMPLETED | Part 1 Cohort 2: Tarlatamab Dose A/Dose C + AMG 404 | 0 | |
| Overall Study | COMPLETED | Part 1 Cohort 3: Tarlatamab Dose A/Dose D + AMG 404 | 1 | |
| Overall Study | COMPLETED | Part 2 Dose Expansion Cohort: Tarlatamab Dose A/Dose B + AMG 404 | 3 | |
| Overall Study | NOT COMPLETED | Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 | 4 | |
| Overall Study | NOT COMPLETED | Part 1 Cohort 2: Tarlatamab Dose A/Dose C + AMG 404 | 5 | |
| Overall Study | NOT COMPLETED | Part 1 Cohort 3: Tarlatamab Dose A/Dose D + AMG 404 | 2 | |
| Overall Study | NOT COMPLETED | Part 2 Dose Expansion Cohort: Tarlatamab Dose A/Dose B + AMG 404 | 5 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04885998/flow